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AbstrACt
Objectives Both prostate cancer (PCa) and type 2 
diabetes mellitus (T2DM) are increasingly prevalent 
conditions, which frequently coexist in men. Here, we set 
out to specifically examine the impact of a PCa diagnosis 
and its treatment on T2DM treatment.
setting This study uses observational data from Prostate 
Cancer database Sweden Traject.
Participants The study was undertaken in a cohort of 
16 778 men with T2DM, of whom 962 were diagnosed 
with PCa during mean follow-up of 2.5 years.
Primary and secondary outcome measures We 
investigated the association between PCa diagnosis and 
escalation in T2DM treatment in this cohort. A treatment 
escalation was defined as a new or change in anti-T2DM 
prescription, as recorded in the prescribed drug register 
(ie, change from diet to metformin or sulphonylurea or 
insulin). We also investigated how PCa diagnosis was 
associated with two treatment escalations. Multivariate 
Cox proportional hazards regression with age as a time 
scale was used while adjusting for educational level and 
initial T2DM treatment.
results We found no association between PCa 
diagnosis and risk of a single treatment escalation (HR 
0.99, 95% CI 0.87 to 1.13). However, PCa diagnosis 
was associated with an increased risk of receiving 
two consecutive T2DM treatment escalations (HR 
1.75, 95% CI 1.38 to 2.22). This increase was 
strongest for men on gonadotropin-releasing hormone 
(GnRH) agonists (HR 3.08, 95% CI 2.14 to 4.40). The 
corresponding HR for men with PCa not on hormonal 
treatment was 1.40 (95% CI 1.03 to 1.92) and for men 
with PCa on antiandrogens 0.91 (95% CI 0.29 to 2.82).
Conclusions Men with T2DM who are diagnosed with 
PCa, particularly those treated with GnRH agonists, were 
more likely to have two consecutive escalations in T2DM 
treatment. This suggests a need for closer monitoring 
of men with both PCa and T2DM, as coexistence of PCa 
and its subsequent treatments could potentially worsen 
T2DM control.
IntrOduCtIOn 
There are over 60 million people who 
have been diagnosed with type 2 diabetes 
mellitus (T2DM) across Europe, and it is 
estimated that over 10% of men in Europe 
have T2DM.1 Prostate cancer (PCa) is the 
the most common cancer in men in Europe, 
with around 417 000 new cases diagnosed 
in 2012.2 As a result, these two increasingly 
prevalent conditions often occur together 
in the same men. Their relationship has 
been extensively studied with respect to the 
effects of T2DM on PCa risk and progres-
sion.3 4 However, conversely the impact of 
a PCa diagnosis on the treatment of T2DM 
has received less attention.
T2DM is associated with increased risk of 
several solid malignancies.5 However, for 
men with T2DM there has been a consistent 
decrease in risk of PCa in several meta-anal-
ysis,3 6 7 as compared with not having T2DM. 
T2DM is, however, also included in the 
cluster of disorders which comprise the 
metabolic syndrome (MetS).8 During the 
last decade, several studies have investi-
gated if MetS is involved in the aetiology 
of PCa.9–11 A meta-analysis of risk of PCa 
related to MetS found a pooled relative risk 
of 1.54 (95% CI 1.23 to 1.94).12 Hence, the 
relationship between PCa and T2DM is not 
fully understood. Finally, the gold standard 
treatment for advanced PCa is androgen 
deprivation therapy (ADT), which has been 
strengths and limitations of this study
 ► Large population design of Prostate Cancer (PCa)    
database.
 ► Large numbers of men with type 2 diabetes (T2DM) 
included.
 ► Inclusion of a large number of men who subsequent-
ly developed PCa (the exposure) as well as informa-
tion on PCa treatment received.
 ► No serial measurements of haemoglobin A1c were 
available, so proxy of escalations in pharmacological 
treatment was used to assess T2DM control.
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shown to increase the risk of T2DM.13 14 The risk is 
highest in men on gonadotropin-releasing hormone 
(GnRH) agonists.13
A recent meta-analysis of glycaemic control in subjects 
with T2DM during and after cancer treatment found 
mixed results, with four studies reporting no increase in 
haemoglobin A1c (HbA1c) and three studies reporting 
an increase in HbA1c after cancer treatment.15 Of those 
three studies where glycaemic control worsened, two 
were in patients with PCa who had received ADT.16 17 The 
largest study was by Keating et al, and it showed an increase 
in HbA1c at 1 and 2 years despite a 20% increased risk of 
receiving additional T2DM medications in men with PCa 
on GnRH agonists.16 With the recent emergence of novel 
treatments that increase survival in men with advanced 
PCa, there is an increasing need to understand how 
PCa treatment affects T2DM control. Here, we aimed to 
further investigate the impact of a PCa treatment on the 
management of T2DM.
MethOds
study population and data collection
Prostate Cancer database (PCBaSe) Sweden 3.0 is based 
on the National Prostate Cancer Register (NPCR) of 
Sweden, which became nationwide in 1998 and covers 98% 
of all newly diagnosed cases of PCa, as compared with the 
Swedish Cancer Register.15 16 NPCR includes information 
on date of diagnosis, age at diagnosis, tumour stage and 
differentiation, serum levels of prostate-specific antigen 
at time of diagnosis. Using the Swedish personal identity 
number, five PCa-free men from the general population 
in Sweden were randomly selected within sets of men 
who matched the index case on birth year and county of 
residence and included in a PCa-free control cohort.15 
Both men with PCa and those in the control cohort 
were subsequently linked to a series of national health-
care registers and demographic databases, including the 
National Diabetes Register (NDR) and the Prescribed 
Drug Register (PDR). PCBaSe Traject includes all data in 
Table 1 Baseline characteristics of all patients and divided by those later diagnosed with PCa and those who were not
All men No PCa PCa
N=16 778 N=15 816 N=962
Age onset of DM (median) Q1–Q3 Q1– Q3 Q1– Q3
71.1 (65.5–77.2) 71.2 (65.6–77.3) 69 (63.1–75.5)
Follow-up years (median) Q1–Q3 Q1–Q3 Q1–Q3
2.5 (1.1–4.3) 2.5 (1.1–4.3) 3.2 (1.5–5.2)
Initial DM treatment % % %
  Diet 9692 57.8 9126 57.7 566 58.8
  Metformin 6373 38 6020 38.1 353 36.7
  Metformin+SU 79 0.5 75 0.5 4 0.4
  SU 634 3.8 595 3.8 39 4.1
HbA1c at DM onset (%) Q1–Q3 Q1–Q3 Q1–Q3
48 43–56 48 43–56 48 43–55
Missing HbA1c (N) % % %
2310 13.8 2208 14 102 10.6
BMI2 median (kg/m2) Q1–Q3 Q1–Q3 Q1–Q3
28.7 26–31.6 28.6 26–31.6 28.7 26.2–31.4
Missing BMI2 (N) % % %
4540 27.1 4305 27.2 235 24.4
Education status % % %
  Low 7402 44.1 6998 44.2 404 42
  Middle 6336 37.8 5976 37.8 360 37.4
  High 2810 16.7 2623 16.6 187 19.4
  Missing 230 1.4 219 1.4 11 1.1
Civil status % % %
  Not married 5649 33.7 5317 33.6 332 34.5
  Married 11 129 66.3 10 499 66.4 630 65.5
BMI, body mass index; DM, diabetes mellitus; HbA1c, haemoglobin A1c; PCa, prostate cancer; Q1, quartile 1; Q3, quartile 3.
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PCBaSe 3.0 but has additional linkages. It focuses specifi-
cally on men diagnosed with PCa between 1992 and 2012 
with information available on their complete treatment 
trajectory.16
Using PCBaSe Traject, we included all men with a 
diagnosis of T2DM without a pre-existing PCa diagnosis, 
taken either from the NDR or those receiving antidiabetic 
medications within the PDR between 2005 and 2014. The 
Research Ethics Board at Umeå University approved this 
study.
The main outcome variable in this study was an esca-
lation in T2DM treatment (ie, change from diet control 
to metformin or sulphonylurea or insulin). Information 
on filled prescriptions of metformin, sulphonylurea 
and insulin were obtained from the PDR using Anatom-
ical Therapeutic Chemical (ATC) codes (insulin-ANA, 
metformin-A10BA/BD, sulphonylurea- A10BB).18 The 
initial T2DM treatment was defined using filled drug 
prescriptions for antidiabetic drugs entered during a 
6-month run-in period following the date of registration 
of T2DM in the NDR. If the same drug was used in two 
consecutive 90-day periods, it was deemed to be the initial 
T2DM treatment. Follow-up started after the run-in and if 
no drug prescriptions had been filled during that period, 
then diet control was deemed to be the initial treatment. 
All men who received insulin as initial treatment were 
excluded from the study, since escalation of insulin doses 
could not be assessed due to an absence of data on dose.
The main exposure variable in this study was a diagnosis 
of PCa in PCBaSe Traject. We also examined PCa treat-
ments, divided into no ADT, antiandrogens (AA) mono-
therapy and GnRH agonists. We specifically focused on 
ADT because it has consistently been found to increase 
the risk of T2DM.13 14 Exposure to these treatments was 
taken from the PDR. If a man received more than one of 
these treatments, they contributed exposure time to each 
category for the duration of that therapy, that is, a man 
could have contributed person-time to the no ADT group 
Table 2 Single treatment changes and event numbers
One treatment change Event number
No change 10 573
Diet ->metformin 3495
Diet ->SU 389
Metformin ->insulin 695
Metformin ->SU 770
Metformin+SU ->insulin 79
SU ->insulin 129
SU ->metformin 212
Diet ->metformin+SU 19
Diet ->insulin 417
SU, sulphonylurea.
Table 3 Two consecutive treatment changes and event 
numbers
Two treatment changes Event numbers
No changes 10 573
One change* 1320
SU ->metformin ->insulin 66
SU ->metformin+SU ->insulin 8
Diet ->metformin ->insulin 314
Diet ->metformin ->SU 450
Diet ->SU ->insulin 60
Diet ->SU ->metformin 96
Metformin ->SU ->insulin 197
*These numbers reflect those who only underwent one change.
SU, sulphonylurea.
Table 4 HRs and 95% CI for a single change of T2DM 
treatment by PCa diagnosis and PCa treatments
Multivariate analysis*
HR 95% CI
PCa diagnosis No PCa 1 (Ref)
PCa 0.99 0.87 to 1.13
PCa treatment No PCa 1 (Ref)
No ADT 0.97 0.83 to 1.14
AA 0.80 0.48 to 1.36
GnRH 1.12 0.86 to 1.47
*Multivariate analysis with age as time scale and adjusted for 
education status and initial diabetes treatment.
AA, antiandrogen; ADT, androgen deprivation therapy; GnRH, 
gonadotropin-releasing hormone agonist; PCa, prostate cancer; 
T2DM, type 2 diabetes mellitus. 
Table 5 HRs and 95% CI for two consecutive changes of 
DM treatment by PCa diagnosis and PCa treatments
Multivariate analysis*
HR 95% CI
PCa diagnosis No PCa 1.00 (Ref)
PCa 1.75 1.38 to 2.22
PCa treatment No PCa 1.00 (Ref)
No ADT 1.40 1.03 to 1.92
AA 0.91 0.29 to 2.82
GnRH 3.08 2.14 to 4.44
PCa diagnosis in relation 
to prior change in T2DM 
treatment
No PCa 1.00 (Ref)
PCa prior to 
one change
1.09 0.78 to 1.54
PCa after 
one change
3.59 2.61 to 4.93
*Multivariate analysis with age as time scale and adjusted for 
education status and initial diabetes treatment.
AA, antiandrogen; ADT,androgen deprivation therapy; GnRH, 
gonadotropin-releasing hormone agonist; PCa, prostate cancer; 
T2DM, type 2 diabetes mellitus. 
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initially and then later to the GnRH agonist or AA expo-
sure group after conversion to hormonal therapy.
Analysis
Multivariate cox proportional hazards regression was 
used to calculate HRs and 95% CI for one and two T2DM 
treatment escalations in men who had and had not 
been diagnosed with PCa. Age was used as a time scale 
and all models were adjusted for educational level and 
initial T2DM treatment. We performed a further analysis 
in which the exposure was defined as type of PCa treat-
ment (as defined above). We also performed an analysis 
examining the risk of consecutive treatment escalations 
in patients whose PCa diagnosis came before and after 
the first treatment change.
All data management was performed with SAS V.9.3 
(SAS Institute) and all data analysis was conducted with R 
V.2.13.2 (R Foundation for Statistical Computing).
results
A total of 16 778 men with T2DM were included in the 
study of whom 962 were diagnosed with PCa during 
follow-up, median of 2.5 years (IQR 1.3 1.1–4.3) (table 1). 
Initially treated with diet control were 9692 men (57%) 
and 6373 (38%) received metformin as initial T2DM 
treatment (table 1). All baseline characteristics were 
similar between men who later were and were not diag-
nosed PCa. Table 2 shows the single treatment escalations 
captured and the event numbers for each change for all 
men. About 6205 treatment changes were seen, the most 
common change was from diet control to metformin 
(3495). Those who had two consecutive treatment escala-
tions (table 3) were 1191 men.
There was no association between PCa diagnosis and 
risk of a single treatment escalation (HR 0.99, 95% CI 0.87 
to 1.13) (table 4). Neither was there any association with 
the type of PCa treatment (no ADT HR 0.97, 95% CI 0.83 
to 1.14, AA HR 0.80, 95% CI 0.48 to 1.36, GnRH agonists 
HR 1.12, 95% CI 0.86 to 1.47) (table 4).
PCa diagnosis was associated with an increased risk of 
two consecutive T2DM treatment escalations (HR 1.75, 
95% CI 1.38 to 2.22) (table 5). This increase was strongest 
in men on GnRH agonists (HR 3.08, 95% CI 2.14 to 4.40). 
The corresponding HR for men with PCa not on ADT was 
1.40 (95% CI 1.03 to 1.92) and for men on AA was 0.91 
(95% CI 0.29 to 2.82) (table 5). The increased risk was 
seen only in men who were diagnosed with PCa after a 
change of T2DM treatment, that is, who were treated with 
a drug (HR 3.59, 95% CI 2.61 to 4.93), compared with 
those who were diagnosed with PCa prior to any change 
in T2DM treatment (HR 1.09, 95% CI 0.78 to 1.54).
dIsCussIOn
In this population-based cohort study, PCa diagnosis was 
associated with an increased risk of two consecutive T2DM 
treatment escalations. The association was strongest in 
men treated with GnRH agonists and was only observed 
in men who were receiving pharmacological treatment 
for their T2DM.
Prior to this study, all studies examining worsening of 
glycaemic control and T2DM treatments following a PCa 
diagnosis have focused solely on men on ADT. In a small 
study of 29 patients with advanced PCa and insulin depen-
dent T2DM on ADT, Haidar et al showed a worsening in 
HbA1c and increasing insulin requirements.17 In a similar 
US study of 77 patients with T2DM and PCa on ADT, 15 
(19.5%) men had a >10% increase in HbA1c.18 However, 
there were no control men in either of these small single 
institution studies. The largest study to date used the 
Veterans Affairs observational cohort to study 2237 pairs 
of propensity matched men with PCa and T2DM who 
were or were not treated with GnRH agonists.16 They 
showed an increase in HbA1c at 1 and 2 years despite a 
20% increased risk of receiving additional T2DM medi-
cations in those receiving GnRH agonists. Most recently a 
case–control study showed no impact of PCa diagnosis on 
mean HbA1c or glucose.19 However, over 70% of patients 
in this study underwent prostatectomy and therefore did 
not receive ADT.
These studies are in line with the findings of our study 
that a diagnosis of PCa worsens glycaemic control in men 
with pre-existing T2DM when looking at the proxy of esca-
lating pharmacological treatment. Worsening of glycaemic 
control was strongest in men on GnRH agonists compared 
with other forms of ADT such as AA. This mirrors what has 
previously been seen with the increased risk of T2DM in 
non-diabetics treated with ADT.13 However, we also show 
an increased risk of two consecutive treatment escalations 
in those who are not receiving any form of ADT. Current 
literature has focused only on those receiving ADT, so 
this is a new finding. This may suggest that there is a true 
disease effect of PCa on glycaemic control, not just as a 
result of treatments received.
We showed no increased risk of a single treatment esca-
lation. The risk was highest in those who already had one 
escalation of treatment prior to the diagnosis of PCa. As 
nearly 60% of our population was initially treated with 
dietary modification, this suggests those who are already 
receiving a pharmacological treatment for T2DM are 
at highest risk of further escalations following a PCa 
diagnosis. This is in concordance with previous studies. 
Keating et al looked specifically at initiation or addition of 
insulin therapy and found a higher rate in men on ADT 
versus men not on ADT (94.5 men per 1000 person-years 
vs 81.2) as a marker of intensification of antidiabetes 
management.16
Use of GnRH agonists decreases insulin sensitivity and 
increases body fat. These physiological effects have been 
shown to occur early after treatment initiation20 and 
although it has not been directly studied it can be hypoth-
esised that similar physiological changes would occur in 
patients with pre-existing diabetes leading to a worsening 
of glycaemic control and the need for escalating pharma-
cological management.
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Strengths of our study include the large popula-
tion design of PCBaSe and the large number of men 
with T2DM included in this study, meaning it has good 
external validity. The design of the study allows for inclu-
sion of a large number of men who subsequently devel-
oped PCa. The linkage to both the NDR and PDR allowed 
detailed data on the initial and subsequent T2DM treat-
ments to be accessed. Unlike previous studies, we had 
detailed data on the type of PCa treatment being received 
and were able to examine GnRH agonists individually, 
not only in combination with other forms of ADT. Weak-
nesses include the lack of repeated measures of HbA1c, 
so although we are able to present median HbA1c at 
T2DM diagnosis, there are insufficient data available to 
examine changes following a PCa diagnosis. However, 
using change in T2DM treatments as a proxy of wors-
ening glycaemic control is a clinically relevant outcome. 
Patients who had insulin-dependent T2DM at diagnosis 
were excluded from the study, as we were unable to 
capture change in insulin doses from the available data. 
However, it is unusual for a person with newly diagnosed 
T2DM to require insulin as first-line treatment. By using a 
6-month run in window, with consecutive 90-day periods, 
to determine initial T2DM treatment, we were still able 
to include any patients who needed a one-off period of 
insulin to rapidly achieve glycaemic control at presenta-
tion before moving on to different forms of maintenance 
treatment. Hence, the numbers lost because of this exclu-
sion were small.
COnClusIOn
Men with T2DM who are diagnosed with PCa, particularly 
those treated with GnRH agonists, were more likely to 
have two consecutive escalations in T2DM treatment. This 
suggests a need for closer monitoring of men with both 
PCa and T2DM, as coexistence of PCa and its subsequent 
treatments could potentially worsen T2DM control.
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